Legal & General Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02B Sell
16,877,626
-488,406
-3% -$28.5M 0.24% 76
2025
Q4
$937M Buy
17,366,032
+290,289
+2% +$14M 0.21% 92
2025
Q3
$770M Buy
17,075,743
+1,317,199
+8% +$61.5M 0.17% 106
2025
Q2
$729M Sell
15,758,544
-707,829
-4% -$34.7M 0.18% 104
2025
Q1
$1B Buy
16,466,373
+340,567
+2% +$19.9M 0.27% 64
2024
Q4
$912M Sell
16,125,806
-546,072
-3% -$30.5M 0.24% 71
2024
Q3
$863M Buy
16,671,878
+138,273
+0.8% +$6.49M 0.23% 78
2024
Q2
$687M Buy
16,533,605
+88,834
+0.5% +$3.97M 0.19% 93
2024
Q1
$892M Sell
16,444,771
-248,254
-1% -$12.6M 0.26% 69
2023
Q4
$857M Sell
16,693,025
-303,238
-2% -$15.9M 0.27% 65
2023
Q3
$986M Sell
16,996,263
-438,424
-3% -$26.9M 0.34% 45
2023
Q2
$1.11B Buy
17,434,687
+856,985
+5% +$57.5M 0.36% 45
2023
Q1
$1.15B Buy
16,577,702
+69,552
+0.4% +$4.91M 0.41% 39
2022
Q4
$1.19B Buy
16,508,150
+6,578
+0% +$496K 0.46% 36
2022
Q3
$1.17B Sell
16,501,572
-551,586
-3% -$40M 0.46% 32
2022
Q2
$1.31B Buy
17,053,158
+674,921
+4% +$51.4M 0.46% 34
2022
Q1
$1.2B Buy
16,378,237
+1,188,644
+8% +$79.8M 0.36% 48
2021
Q4
$947M Sell
15,189,593
-632,124
-4% -$37.1M 0.29% 61
2021
Q3
$936M Buy
15,821,717
+741,489
+5% +$48.8M 0.3% 58
2021
Q2
$1.01B Buy
15,080,228
+697,349
+5% +$45.5M 0.34% 54
2021
Q1
$908M Sell
14,382,879
-85,320
-0.6% -$5.31M 0.34% 55
2020
Q4
$897M Buy
14,468,199
+155,917
+1% +$9.59M 0.35% 51
2020
Q3
$863M Sell
14,312,282
-447,296
-3% -$26.9M 0.39% 50
2020
Q2
$868M Sell
14,759,578
-689,293
-4% -$41.2M 0.42% 46
2020
Q1
$862M Buy
15,448,871
+234,035
+2% +$14.3M 0.5% 35
2019
Q4
$977M Buy
15,214,836
+4,558,218
+43% +$261M 0.47% 34
2019
Q3
$540M Buy
10,656,618
+66,392
+0.6% +$3.12M 0.28% 69
2019
Q2
$480M Buy
10,590,226
+415,853
+4% +$19.4M 0.26% 78
2019
Q1
$485M Buy
10,174,373
+1,605,928
+19% +$80M 0.28% 72
2018
Q4
$445M Buy
8,568,445
+474,820
+6% +$25.5M 0.35% 57
2018
Q3
$502M Buy
8,093,625
+121,647
+2% +$7.22M 0.36% 52
2018
Q2
$441M Sell
7,971,978
-66,471
-0.8% -$3.59M 0.34% 55
2018
Q1
$508M Sell
8,038,449
-445,262
-5% -$28.6M 0.39% 48
2017
Q4
$520M Sell
8,483,711
-138,941
-2% -$8.69M 0.38% 49
2017
Q3
$550M Buy
8,622,652
+191,304
+2% +$11.2M 0.41% 46
2017
Q2
$470M Buy
8,431,348
+217,920
+3% +$11.9M 0.38% 46
2017
Q1
$447M Buy
8,213,428
+335,795
+4% +$18.4M 0.38% 45
2016
Q4
$460M Sell
7,877,633
-33,535
-0.4% -$1.83M 0.43% 42
2016
Q3
$427M Sell
7,911,168
-20,912
-0.3% -$1.34M 0.43% 45
2016
Q2
$583M Buy
7,932,080
+347,094
+5% +$24.5M 0.61% 35
2016
Q1
$485M Buy
7,584,986
+100,013
+1% +$6.31M 0.54% 39
2015
Q4
$515M Buy
7,484,973
+74,490
+1% +$4.92M 0.58% 36
2015
Q3
$439M Buy
7,410,483
+294,001
+4% +$18.7M 0.53% 37
2015
Q2
$473M Sell
7,116,482
-173,987
-2% -$11.5M 0.56% 36
2015
Q1
$470M Buy
7,290,469
+66,023
+0.9% +$4.13M 0.56% 36
2014
Q4
$427M Sell
7,224,446
-175,520
-2% -$9.9M 0.5% 40
2014
Q3
$379M Sell
7,399,966
-290,152
-4% -$14.5M 0.45% 47
2014
Q2
$373M Buy
7,690,118
+318,205
+4% +$15.7M 0.43% 47
2014
Q1
$383M Sell
7,371,913
-143,351
-2% -$7.63M 0.47% 44
2013
Q4
$399M Sell
7,515,264
-48
-0% -$2.44K 0.48% 42
2013
Q3
$348M Buy
7,515,312
+16,727
+0.2% +$734K 0.46% 45
2013
Q2
$335M Buy
+7,498,585
New +$326M 0.46% 42

Other funds holding BMY

Legal & General Group's BMY Position: Q1 2026 in Review

Legal & General Group reduced its Bristol-Myers Squibb (BMY) stake by 2.8% in Q1 2026, selling an estimated $28.5M and leaving 16,877,626 shares worth $1.02B. The position accounts for 0.24% of the portfolio, ranked #76.

Legal & General Group first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.31B in Q2 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Legal & General Group held 16,877,626 shares of Bristol-Myers Squibb worth $1.02B as of Q1 2026.
  • Legal & General Group sold 488,406 Bristol-Myers Squibb shares in Q1 2026, an estimated $28.5M.
  • Bristol-Myers Squibb made up 0.24% of Legal & General Group's portfolio in Q1 2026, its #76 holding.
  • Legal & General Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Legal & General Group's Bristol-Myers Squibb position peaked at $1.31B in Q2 2022.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.